Wyeth to slash another 1,200 jobs

And the ax is falling again. Wyeth notified employees last Friday than another 1,200 jobs will be slashed from the payroll. That's on top of the 1,240 sales jobs slated for elimination last month.

The cutbacks are part of "Project Impact," a restructuring plan Wyeth hopes will help it grapple with impending generic competition and FDA-approval setbacks. Blockbuster heartburn treatment Protonix has already been losing to generic competition, so much so that the company introduced its own generic version. In 2007, the FDA declined to approve Wyeth's osteoporosis candidate bazedoxifene (Viviant) and its schizophrenia med bifeprunox. Though Wyeth finally got its Effexor replacement Pristiq approved for depression, it was sent back to the drawing board on an indication for menopause.

- see the news at Pharmalot

Related Articles:
Top 8 layoffs of 2007
1,200 Wyeth reps out of work

Wyeth mulls 5,000 job cuts
Wyeth stumbles badly trying to develop new drugs

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.